← All trials
NCT05153070
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2022
- Primary completion
- Mar 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Dec 10, 2021
- Last posted
- Dec 10, 2021
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Iltoo PharmaCollaborator
- Assistance Publique - Hôpitaux de ParisStudy director
- Assistance Publique - Hôpitaux de ParisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.